24/03/2023
World TB Day
Today is #WorldTBDay, a day to raise awareness about the devastating impact of #tuberculosis –…
Read More
Our facilities are engineered to manufacture small-customized clinical batches under GMPs.
RUTI® vaccine, our own project for fighting against Tuberculosis.
Mission & Values
Our mission is to guide you and your product from early stages of development to the first clinical phases.
Innovation
We are committed to new approaches, capable of providing real solutions to develop of innovative drug products.
Flexibility
Archivel Farma is an organization that learns from experience and constantly adapts to a changing and challenging environment.
Quality
A team with the highest professional standards guarantees the quality of our services and the rigor of the results.
Facilities
Our facilities are carefully engineered and uniquely built to support and enable early phase development for injectables and freeze dried products.
Commitment
We are committed to take your product forwards to early clinical stages, providing agile and flexible and customized services.
Leadership team
Ever-growing team of highly qualified pharmacy, biology and biopharmaceutical experts to find smart solutions to the challenging area of innovate drug development.
Team
Mercè Amat
Head of Research & Development
Leader of RUTI project
BIO
Mercè Amat has a PhD in Biochemistry from the University of Barcelona. She has broad professional experience in the sectors of bioscience and pharmaceuticals. For more than nine years, she led biological projects in respiratory and arthritis areas in the Research Departments at Almirall and at Menarini before joining Archivel Farma as Head of R&D in 2008. Currently, the focus of her work is on the development of RUTI®, most notably in the improvement of the manufacturing process and the product characterization. She is also conducting research on the use of RUTI® beyond tuberculosis.
Joan Casanovas
Head of the Production
Leader of Services
BIO
Joan Casanovas holds a Bachelor’s degree in Biology by the University of Barcelona. In recent years he has developed his professional career in London, working in the Cellular Therapy department at Great Ormond Street Hospital and Gene Therapy at University College London (UCL). He was involved in the translation of Lymphocyte manufacture for immunotherapy clinical trials, from research to GMP standards. Joan joined Archivel’s team in October 2019 as Production Manager, with the goal of manufacturing RUTI® vaccine.
Janina Duch
Quality Control Manager
BIO
Janina Duch is a Technician in Analysis and Quality Control from the IES Narcís Monturiol in Barcelona. With a professional trajectory of more than 10 years of experience working in the pharmaceutical industry, and numerous specific training courses around Quality, she has worked in companies as Sandoz and Biofarm Biotechnology.
Funding
Private Funding
Archivel Farma is a private company, founded in 2005, which has as main investors TGT Group and Archivel Technologies, and has a minority participation of Laboratorios Reig Jofré.
In its different stages of development, the company has received financial support from investment funds such as FonsInnocat (BcnHighGrowth); Agora Invest; Inversions Valor Afegit; and Etios Capital Invest. All of them exited Archivel Farma in 2011.
Public Funding
The company has also received public funds from CDTI (Center for the Development of Industrial Technology); ENISA (Empresa Nacional de Innovación, SA); the missing Genoma España Foundation, now FECYT; and ACCIÓ, Catalan Agency for Business Competitiveness, as well as European funds through H2020 Research and Innovation projects.
Partnership
Archivel Farma co-develop Advanced therapy medicinal products (ATMPs) in a partnership with Reig Jofre Lab
Archivel Farma collaborates with COMSER Pharma in the development of freeze dried biological products as the manufacturer of clinical batches.
Archivel on the media
TV3, QuèQuiCom –2016
TV3, Trenta Minuts –2011
News
15/02/2023
The STRITUVAD project has been completed
The STRITUVAD (In Silico TRIals for TUberculosis VAccine Development) project has been completed. It has…
Read More
30/09/2022
A new clinical trial, CONSTAN-ARG, will test the effectiveness of the #RUTI® vaccine
A new clinical trial, CONSTAN-ARG, will test the effectiveness of the #RUTI® vaccine to shorten treatment…
Read More
22/10/2021
The STriTuVaD Consortium is proud to announce the recruitment of the First Patient in the STriTuVaD Clinical Trial of RUTI® Vaccine for Tuberculosis (TB)
The Spanish biotech company Archivel Farma has officially begun the clinical trial of its therapeutic…
Read More
08/04/2020
Archivel Farma’s RUTI® vaccine to start a clinical trial to increase the immunity of healthcare professionals exposed to the risk of COVID-19
The clinical trial will be carried out at the Germans Trias i Pujol Hospital in…
Read More
05/11/2019
Extension of the authorization for the manufacture of medicines
As of 30th October 2019, Archivel Farma has obtained from the Spanish Health Authority the authorization…
Read More
20/02/2019
Archivel Farma at the annual TBVI meeting
On January 29, Archivel Farma, represented by its CEO, Olga Rúe, and Dr. Pere Joan…
Read More
04/02/2019
Inauguration meeting of STriTuVaD project
Olga Rue, CEO of Archivel Farma, and Dr Pere Joan Cardona, Scientific advisor of the…
Read More
15/01/2019
Archivel participates in the STriTuVaD consortium
Archivel Farma is one of the eight partners of STriTuVad consortium, whose overall goal is…
Read More
23/03/2018
Archivel Farma launches its new website on the World TB Day 2018
Archivel Farma has decide to launch its new website to coincide with the World TB…
Read More